Cyanidin - NutraPedia

Back to Table of Contents

Cyanidin Overview

Cyanidin is a natural organic compound belonging to the anthocyanins, a type of flavonoid pigment that contributes to the red, purple, and blue colors of many fruits and flowers.

Research Overview

Cyanidin-3-glucoside (C3G) is the most widely occurring anthocyanin in plants and has been studied extensively in the context of (i) food science/technology (as a natural colorant whose stability depends strongly on pH, light, temperature, and molecular structure, with chromatography commonly used for extraction and quantification) and (ii) health-related bioactivity typical of anthocyanins/polyphenols (antioxidant, anti-inflammatory, and antimicrobial effects, with proposed involvement of pathways such as free-radical scavenging, cyclooxygenase, MAPK signaling, and inflammatory cytokine signaling). A major focus has also been on pharmacokinetics and biotransformation: human and review-level evidence indicates anthocyanins have a distinctive ADME profile compared with other flavonoids, with absorption possible from both stomach and intestine, extensive first-pass metabolism, and substantial formation of circulating phenolic acid–type metabolites that may occur at higher concentrations than the parent compound. Microbiota-mediated degradation in the large intestine is repeatedly highlighted as a key determinant of exposure to downstream metabolites and potential local (colonic) effects.

The strongest direct evidence in the studies reviewed here comes from controlled human ADME work using isotopically labeled C3G, showing measurable systemic appearance of labeled metabolites and elimination over up to 48 hours, with inter-individual variability and a reported relative bioavailability on the order of ~12% when considering urinary and breath recovery. This supports the conclusion that C3G-derived compounds are more bioavailable than historically assumed, but largely as metabolites (e.g., phenolic, hippuric, phenylacetic, and phenylpropenoic acids) rather than intact C3G. For efficacy, the most mechanistically detailed evidence presented is preclinical: in rodent and cell models of myocardial ischemia–reperfusion injury, C3G reduced infarct-related outcomes and markers of oxidative stress and ferroptosis, with proposed regulation of autophagy/ferroptosis-associated proteins (e.g., Beclin1-related signaling, GPX4, iron-handling proteins). Additional preclinical work in diet-induced fatty liver disease models suggests that phenolic metabolites of C3G (notably protocatechuic acid) may mediate metabolic and inflammatory improvements via gut microbiota modulation, and structure–activity summaries indicate C3G can inhibit α-amylase in a manner sensitive to glycosylation patterns.

Key gaps include (i) more human intervention trials that link defined C3G dosing to clinically meaningful endpoints (cardiometabolic, hepatic, or vascular outcomes) while simultaneously measuring metabolite profiles, (ii) clarification of which metabolites drive which biological effects (parent compound vs phenolic acids such as protocatechuic acid), and (iii) mechanistic validation in humans of microbiota-dependent pathways suggested by animal and fecal microbiota transplantation studies. Additional needs are standardized analytical methods and reporting (to address variability in recovery/bioavailability estimates), dose–response characterization, and evaluation of how food matrix, processing, and pigment stability (pH/light/temperature) alter real-world exposure and efficacy. Overall, the field is strongest in compositional/technological characterization and in mechanistic preclinical biology, with human evidence currently most robust for ADME and metabolite persistence rather than definitive therapeutic effects.

1. What conditions has Cyanidin 3-glucoside been studied for?

  • Cardiovascular health (broad): Anthocyanin-rich foods are associated with reduced cardiovascular disease risk, and C3G is highlighted as a major dietary anthocyanin. Human work has also focused on its absorption/metabolism relevant to cardiovascular effects.

  • Myocardial ischemia–reperfusion (I/R) injury: Studied in rats and in H9c2 cardiomyocyte models (oxygen-glucose deprivation/reoxygenation).

  • Acute kidney injury (AKI) due to ischemia–reperfusion: Studied in I/R-AKI mice and in HK-2 renal tubular cells under hypoxia/reoxygenation.

  • Metabolic associated fatty liver disease (MAFLD): Studied in high-fat diet mouse models, including work examining C3G and especially its phenolic metabolite protocatechuic acid (PCA), plus fecal microbiota transplantation experiments (for PCA).

  • Diabetes-related outcomes: Mentioned as having hypoglycemic effects in diabetic rats (black rice-derived C3G) and being investigated for diabetic nephropathy (DN) in a rat model (abstract truncated, so outcomes are not fully available here).

  • Oxidative stress-related conditions (broad): Reviews describe antioxidant/cytoprotective roles (e.g., DNA damage, apoptosis, inflammatory conditions) and emphasize Nrf2/ARE pathway regulation in vivo.

  • Digestive enzyme inhibition relevant to glycemic control: C3G is discussed in the context of inhibiting α-amylase (structure–activity review).

  • ADME / bioavailability in humans: A controlled human study administered 500 mg isotopically labeled C3G to characterize absorption, metabolism, and elimination.

2. Does it work in treating those conditions? Summarize the evidence.

  • Myocardial I/R injury (preclinical evidence: supportive)

    • In rats, C3G administration reduced infarct area and improved several injury-related readouts (e.g., pathological alterations and ST-segment elevation) and reduced oxidative stress and ferroptosis-related protein expression.

    • In H9c2 cells (OGD/R model), C3G reduced oxidative stress markers and altered ferroptosis/autophagy-related signals (e.g., increased GPX4 and FTH1; decreased TfR1; reduced LC3II/LC3I and autophagosome number). Mechanistically, it was linked to ubiquitination of Beclin1 and suppression of USP19/LC3II.

    • Limitations: animal/cell models only in the studies reviewed here; no human clinical outcomes for myocardial I/R are provided.

  • I/R-related AKI (preclinical evidence: supportive)

    • In mice and HK-2 cells, C3G inhibited ferroptosis features: reduced free iron accumulation, lipid peroxidation markers (4-HNE, lipid ROS, MDA), and ACSL4; increased GPX4 and glutathione (GSH).

    • Mechanism: effects were dependent on AMPK activation—an AMPK inhibitor (CC) substantially reduced the nephroprotective effect.

    • Limitations: preclinical models; no human AKI trials are provided.

  • MAFLD (evidence points more strongly to metabolites than parent C3G)

    • In high-fat diet mice, the study first evaluated C3G and its phenolic metabolites and reported that protocatechuic acid (PCA) showed a significant positive effect.

    • PCA reduced hepatic and intraperitoneal fat deposition, lowered AST/ALT and inflammatory cytokines, improved HDL-c/LDL-c ratio, and shifted gut microbiota features (e.g., reduced Firmicutes/Bacteroidetes ratio). FMT experiments were used to explore microbiota involvement (details truncated).

    • Interpretation: this supports a model where C3G-derived metabolites (rather than intact C3G alone) may drive some metabolic-liver benefits.

    • Limitations: mouse data; the study does not provide clear efficacy outcomes for C3G itself versus PCA beyond noting PCA’s stronger effect.

  • Cardiovascular risk reduction (human evidence in studies: indirect)

    • Reviews state that anthocyanin-rich food consumption is associated with reduced cardiovascular disease risk, but the studies reviewed here do not include a clinical outcomes trial of C3G for cardiovascular endpoints.

    • The human labeled-C3G study demonstrates that C3G is metabolized into multiple circulating phenolic acids and related metabolites that persist up to 48 hours—supporting biological plausibility for systemic effects, but not proving clinical benefit.

  • Glycemic control via α-amylase inhibition (mostly mechanistic/in vitro)

    • A structure–activity review reports C3G showed higher α-amylase inhibition than cyanidin and some other glycosides, while cyanidin-3,5-diglucoside had no inhibitory activity.

    • Limitations: enzyme inhibition does not necessarily translate to clinically meaningful glucose lowering; no human glycemic trials are provided in these studies.

  • Diabetic nephropathy (insufficient information in provided text)

    • The DN abstract indicates a rat model and dosing (10 and 20 mg/kg) but is truncated before outcomes; therefore efficacy cannot be concluded from the provided material.

3. What health benefits does it have?

  • Antioxidant and cytoprotective effects

    • Reviews describe antioxidative activity and protection against oxidative stress-induced disorders; in vivo effects are often framed through regulation of the Nrf2/ARE pathway.

    • In I/R models (heart and kidney), C3G reduced oxidative stress and lipid peroxidation markers and increased endogenous antioxidant defenses (e.g., GSH, GPX4).

  • Anti-inflammatory effects (preclinical)

    • In MAFLD mouse work (noting PCA as a key metabolite), inflammatory cytokines (e.g., IL-1β, IL-2, IL-6, TNF-α, MCP-1) were reduced.

    • Broader anthocyanin reviews cite modulation of inflammatory signaling pathways (e.g., inflammatory cytokine signaling; MAPK; cyclooxygenase pathways).

  • Potential cardioprotection in ischemia–reperfusion injury (preclinical)

    • Rat and cell studies suggest reduced infarct size and suppression of ferroptosis/autophagy-related injury pathways.

  • Potential nephroprotection in ischemia–reperfusion AKI (preclinical)

    • Mouse and cell data indicate inhibition of ferroptosis via AMPK activation, with improved ferroptosis biomarkers (lower ACSL4, higher GPX4, reduced lipid ROS/MDA/4-HNE).

  • Gut microbiota–linked metabolic effects (evidence stronger for metabolites)

    • C3G is extensively metabolized into phenolic acids (human ADME study; review articles), and mouse MAFLD work suggests at least one metabolite (PCA) can beneficially modulate gut microbiota and lipid/inflammatory outcomes.

  • Bioavailability and sustained metabolite exposure (human pharmacokinetic benefit)

    • After 500 mg labeled C3G in humans, labeled metabolites peaked around ~10 hours and persisted in circulation up to 48 hours; relative bioavailability was reported as ~12.4% (with labeled carbon recovered in urine and breath).

    • Metabolites included phenolic, hippuric, phenylacetic, and phenylpropenoic acids—often found at higher concentrations than the parent compound (as also emphasized in the ADME review).

4. Does it have any downsides or side effects?

The studies reviewed here contain very limited direct safety/side-effect reporting for C3G in humans.

  • Human ADME study: Eight men consumed 500 mg isotopically labeled C3G with extensive sampling over 48 hours; the study reports recovery, metabolite profiles, and kinetics but does not describe adverse events or tolerability outcomes.

  • Variability in metabolism/excretion: The labeled-carbon recovery ranged widely across participants (15.1% to 99.3%), suggesting large inter-individual differences in absorption/metabolism that could affect response and possibly tolerability, though side effects are not reported.

  • General limitations: Many claimed benefits come from cell/animal models and mechanistic reviews; these do not establish safety at supplemental doses in diverse human populations (e.g., pregnancy, kidney/liver disease, polypharmacy).

  • Drug/supplement interaction considerations (not directly tested here): Because anthocyanins and metabolites can influence inflammatory and oxidative pathways (and possibly transporters per the ADME review), interactions are plausible but not evidenced in these studies.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic findings are reported in the studies reviewed here (i.e., no genotype-stratified responses, no specific gene variants linked to efficacy or adverse effects).

  • What can be inferred (limited): The human labeled-C3G study showed very large inter-individual variability in labeled-carbon recovery and metabolite kinetics, which could be influenced by genetics (e.g., metabolizing enzymes/transporters) and/or gut microbiome differences, but the study did not test genetic variants.

  • Bottom line: Based on these studies alone, there is insufficient evidence to say C3G is beneficial or harmful for any specific genetic variation.

Summary of Research on Cyanidin

Cyanidin (Cy) and its glycosides (CyG), such as cyanidin-3-glucoside (Cy-3-glc), are anthocyanins responsible for the vibrant colors in various fruits and flowers. These compounds are found in foods like vegetables, fruits, and red wines and are consumed regularly. Studies have investigated their absorption, metabolism, and potential health benefits, which include anti-cancer, cardiovascular protection, anti-inflammatory, anti-obesity, and anti-diabetic properties. However, Cy and CyG have low bioavailability, and further research is needed to fully understand their health effects.

Research in both animals and humans has shown that Cy and CyG can be absorbed into the bloodstream, albeit with a limited capacity. Different forms, such as glucuronides, sulfates, and methylated derivatives, have been detected in plasma and urine. The sodium-dependent glucose transporter is one mechanism through which these anthocyanins cross intestinal cells.

The metabolism of Cy and CyG leads to various derivatives, with protocatechuic acid being a significant metabolite. These compounds and their metabolites contribute to the plasma's antioxidant capacity. In the gastrointestinal tract, anthocyanins mainly remain as glycosides, with aglycones detected in small amounts. The stability of anthocyanins is influenced by their structure, with acylated forms showing more stability under digestive conditions.

Cyanidin also exhibits effects on adipocytes by increasing the secretion of adipocytokines and enhancing gene expression. Studies in obese and diabetic mice have demonstrated that cyanidin compounds can reduce obesity, improve insulin sensitivity, and decrease fat accumulation in the liver. Their potential therapeutic properties have been linked to the activation of AMP-activated protein kinase (AMPK) and the inhibition of certain signaling pathways related to inflammation and metabolism.

Overall, cyanidin and its derivatives hold promise as dietary compounds that may offer health benefits. However, the complexity of their absorption and metabolism necessitates further studies to clarify these processes and their implications for human health.

References:


  1. Absorption and metabolism of cyanidin-3-glucoside and cyanidin-3-rutinoside extracted from wild mulberry (Morus nigra L.) in rats
  2. Bioavailability, antioxidant and biological properties of the natural free-radical scavengers cyanidin and related glycosides
  3. Protocatechuic acid is the major human metabolite of cyanidin-glucosides
  4. Anthocyanins from red cabbage--stability to simulated gastrointestinal digestion
  5. Blue flower color development by anthocyanins: from chemical structure to cell physiology
  6. Anthocyanins: structural characteristics that result in unique metabolic patterns and biological activities
  7. The stomach as a site for anthocyanins absorption from food
  8. Orally administered delphinidin 3-rutinoside and cyanidin 3-rutinoside are directly absorbed in rats and humans and appear in the blood as the intact forms
  9. Absorption and metabolism of cyanidin 3-O-beta-D-glucoside in rats
  10. Anthocyanins are efficiently absorbed from the small intestine in rats
  11. Hypoglycemic activity of a novel anthocyanin-rich formulation from lowbush blueberry, Vaccinium angustifolium Aiton
  12. Plasma and urine responses are lower for acylated vs nonacylated anthocyanins from raw and cooked purple carrots
  13. Pharmacokinetics of anthocyanins and ellagic acid in healthy volunteers fed freeze-dried black raspberries daily for 7 days
  14. Blackberry anthocyanins are mainly recovered from urine as methylated and glucuronidated conjugates in humans
  15. Urinary pharmacokinetics of cyanidin glycosides in healthy young men following consumption of elderberry juice
  16. Absorption and excretion of black currant anthocyanins in humans and watanabe heritable hyperlipidemic rabbits
  17. Anthocyanin glycosides from berry fruit are absorbed and excreted unmetabolized by both humans and rats
  18. Bioavailability of anthocyanidin-3-glucosides following consumption of red wine and red grape juice
  19. Bioavailability of anthocyanidin-3-glycosides following consumption of elderberry extract and blackcurrant juice
  20. Absorption of acylated anthocyanins in rats and humans after ingesting an extract of Ipomoea batatas purple sweet potato tuber
  21. Anthocyanins exist in the circulation primarily as metabolites in adult men
  22. Anthocyanin metabolites in human urine and serum
  23. Fate of anthocyanins and antioxidant capacity in contents of the gastrointestinal tract of weanling pigs following black raspberry consumption
  24. Urinary excretion of black raspberry (Rubus occidentalis) anthocyanins and their metabolites
  25. Aglycones and sugar moieties alter anthocyanin absorption and metabolism after berry consumption in weanling pigs
  26. The bioactivity of dietary anthocyanins is likely to be mediated by their degradation products
  27. Thermal degradation of anthocyanins and its impact on color and in vitro antioxidant capacity
  28. Anthocyanin enhances adipocytokine secretion and adipocyte-specific gene expression in isolated rat adipocytes
  29. Cyanidin 3-glucoside attenuates obesity-associated insulin resistance and hepatic steatosis in high-fat diet-fed and db/db mice via the transcription factor FoxO1
  30. FoxO1: a molecule for all seasons
  31. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle
  32. Cyanidin-3-O-β-glucoside improves obesity and triglyceride metabolism in KK-Ay mice by regulating lipoprotein lipase activity
  33. Cyanidin-3-O-β-glucoside and protocatechuic acid exert insulin-like effects by upregulating PPARγ activity in human omental adipocytes
  34. Dietary cyanidin 3-O-beta-D-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice
  35. Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1 signaling pathway in vitro
  36. Cyanidin-3-glucoside suppresses TNF-α-induced cell proliferation through the repression of Nox activator 1 in mouse vascular smooth muscle cells: involvement of the STAT3 signaling
  37. Delphinidin and cyanidin inhibit PDGF(AB)-induced VEGF release in vascular smooth muscle cells by preventing activation of p38 MAPK and JNK
  38. Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice
  39. Cyanidin 3-glucoside protects 3T3-L1 adipocytes against H2O2- or TNF-alpha-induced insulin resistance by inhibiting c-Jun NH2-terminal kinase activation
  40. Cyanidin-3-glucoside, a natural product derived from blackberry, exhibits chemopreventive and chemotherapeutic activity
  41. Induction of apoptosis in cancer cells by Bilberry (Vaccinium myrtillus) and the anthocyanins
  42. Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice
  43. Anthocyanin-rich extracts inhibit multiple biomarkers of colon cancer in rats
  44. Effect of cyanidin-3-glucoside and an anthocyanin mixture from bilberry on adenoma development in the ApcMin mouse model of intestinal carcinogenesis--relationship with tissue anthocyanin levels
  45. Enhanced absorption of anthocyanins after oral administration of phytic acid in rats and humans
  46. Antioxidant capacity interactions and a chemical/structural model of phenolic compounds found in strawberries
  47. Anthocyanidins and anthocyanins: colored pigments as food, pharmaceutical ingredients, and the potential health benefits.
    Hock Eng Khoo, Azrina Azlan, Sou Teng Tang, See Meng Lim (2017) - Food & nutrition research
  48. Polyphenols and their applications: An approach in food chemistry and innovation potential.
    Fábio Fernandes de Araújo, David de Paulo Farias, Iramaia Angélica Neri-Numa, Glaucia Maria Pastore (2021) - Food chemistry
  49. Human metabolism and elimination of the anthocyanin, cyanidin-3-glucoside: a (13)C-tracer study.
    Charles Czank, Aedín Cassidy, Qingzhi Zhang, Douglas J Morrison, Tom Preston, Paul A Kroon, Nigel P Botting, Colin D Kay (2013) - The American journal of clinical nutrition
  50. Bioavailability of anthocyanins.
    Jim Fang (2014) - Drug metabolism reviews
  51. Protection against Metabolic Associated Fatty Liver Disease by Protocatechuic Acid.
    Jijun Tan, Ruizhi Hu, Jiatai Gong, Chengkun Fang, Yanli Li, Ming Liu, Ziyu He, De-Xing Hou, Hongfu Zhang, Jianhua He, Shusong Wu (2023) - Gut microbes
  52. A review on structure-activity relationship of dietary polyphenols inhibiting α-amylase.
    Jianbo Xiao, Xiaoling Ni, Guoyin Kai, Xiaoqing Chen (2013) - Critical reviews in food science and nutrition
  53. The Protective Effect of Cyanidin-3-Glucoside on Myocardial Ischemia-Reperfusion Injury through Ferroptosis.
    Xin Shan, Zhi-Yang Lv, Meng-Jiao Yin, Jing Chen, Jie Wang, Qi-Nan Wu (2021) - Oxidative medicine and cellular longevity
  54. Natural Polyphenol Recovery from Apple-, Cereal-, and Tomato-Processing By-Products and Related Health-Promoting Properties.
    Katalin Szabo, Laura Mitrea, Lavinia Florina Călinoiu, Bernadette-Emőke Teleky, Gheorghe Adrian Martău, Diana Plamada, Mihaela Stefana Pascuta, Silvia-Amalia Nemeş, Rodica-Anita Varvara, Dan Cristian Vodnar (2022) - Molecules (Basel, Switzerland)
  55. Health benefits of cyanidin-3-glucoside as a potent modulator of Nrf2-mediated oxidative stress.
    Sofia Rahman, Shimy Mathew, Pooja Nair, Wafaa S Ramadan, Cijo George Vazhappilly (2021) - Inflammopharmacology
  56. Cyanidin-3-glucoside inhibits ferroptosis in renal tubular cells after ischemia/reperfusion injury via the AMPK pathway.
    Yi-Wei Du, Xiao-Kang Li, Ting-Ting Wang, Lu Zhou, Hui-Rong Li, Lan Feng, Heng Ma, Hong-Bao Liu (2023) - Molecular medicine (Cambridge, Mass.)
  57. Small Brazilian wild fruits: Nutrients, bioactive compounds, health-promotion properties and commercial interest.
    Iramaia Angélica Neri-Numa, Renata A Soriano Sancho, Ana Paula Aparecida Pereira, Glaucia Maria Pastore (2018) - Food research international (Ottawa, Ont.)
  58. A review of recent advances on cyanidin-3-glucoside: the biotransformation, absorption, bioactivity and applications of nano-encapsulation.
    Mengyu Yang, Abdullah, Naveed Ahmad, Muhammad Hussain, Xiaoqin Lu, Jie Xu, Hao Zhong, Rongfa Guan (2023) - Food & function
  59. Cyanidin-3-glucoside activates Nrf2-antioxidant response element and protects against glutamate-induced oxidative and endoplasmic reticulum stress in HT22 hippocampal neuronal cells.
    Monruedee Sukprasansap, Pithi Chanvorachote, Tewin Tencomnao (2020) - BMC complementary medicine and therapies
  60. Effects of in vitro fecal fermentation on the metabolism and antioxidant properties of cyanidin-3-O-glucoside.
    Bulei Wang, Xin Tang, Bingyong Mao, Qiuxiang Zhang, Fengwei Tian, Jianxin Zhao, Wei Chen, Shumao Cui (2024) - Food chemistry
  61. Cellular uptake, transport mechanism and anti-inflammatory effect of cyanidin-3-glucoside nanoliposomes in Caco-2/RAW 264.7 co-culture model.
    Mengyu Yang, Xiaoqin Lu, Jie Xu, Xiaofeng Liu, Wei Zhang, Rongfa Guan, Hao Zhong (2022) - Frontiers in nutrition
  62. Effects of mannoprotein on the stability and in vitro digestion of cyanidin-3-glucoside.
    Meizhi Wan, Sixu Lin, Chang Tan, Mingyue Wang, Yuqi Tong, Yang Zhao, Yanwen Kong, Haotian Deng, Xianjun Meng, Yan Ma (2023) - Food chemistry
  63. Biological activities of extracts from Chinese bayberry (Myrica rubra Sieb. et Zucc.): a review.
    Chongde Sun, Huizhong Huang, Changjie Xu, Xian Li, Kunsong Chen (2013) - Plant foods for human nutrition (Dordrecht, Netherlands)
  64. Cyanidin-3-glucoside attenuates the angiogenesis of breast cancer via inhibiting STAT3/VEGF pathway.
    Xiao Ma, Shilong Ning (2019) - Phytotherapy research : PTR
  65. Enzymatic acylation of cyanidin-3-glucoside with fatty acid methyl esters improves stability and antioxidant activity.
    Pingling Zhang, Shuang Liu, Zhengang Zhao, Lijun You, Mark D Harrison, Zhanying Zhang (2021) - Food chemistry


Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!